NO20014130L - Epitopes or mimotopes derived from the C <epsilon> 2 domain of IgE, its antagonists and their therapeutic uses - Google Patents

Epitopes or mimotopes derived from the C <epsilon> 2 domain of IgE, its antagonists and their therapeutic uses

Info

Publication number
NO20014130L
NO20014130L NO20014130A NO20014130A NO20014130L NO 20014130 L NO20014130 L NO 20014130L NO 20014130 A NO20014130 A NO 20014130A NO 20014130 A NO20014130 A NO 20014130A NO 20014130 L NO20014130 L NO 20014130L
Authority
NO
Norway
Prior art keywords
epsilon
ige
epitopes
antagonists
domain
Prior art date
Application number
NO20014130A
Other languages
Norwegian (no)
Other versions
NO20014130D0 (en
Inventor
Michael Dyson
Martin Friede
Judith Greenwood
Ellen Hewitt
Alan Lamont
Sean Mason
Roger Randall
William Gordon Turnell
Marcelle Paulette Van Mechelen
Carlota Vinals Y De Bassols
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Publication of NO20014130D0 publication Critical patent/NO20014130D0/en
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20014130L publication Critical patent/NO20014130L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014130A 1999-02-25 2001-08-24 Epitopes or mimotopes derived from the C <epsilon> 2 domain of IgE, its antagonists and their therapeutic uses NO20014130L (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody
PCT/EP2000/001455 WO2000050460A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20014130D0 NO20014130D0 (en) 2001-08-24
NO20014130L true NO20014130L (en) 2001-09-13

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014130A NO20014130L (en) 1999-02-25 2001-08-24 Epitopes or mimotopes derived from the C <epsilon> 2 domain of IgE, its antagonists and their therapeutic uses

Country Status (19)

Country Link
EP (1) EP1155037A1 (en)
JP (1) JP2004538238A (en)
KR (1) KR20020007313A (en)
CN (1) CN1348466A (en)
AR (1) AR029336A1 (en)
AU (1) AU2672700A (en)
BR (1) BR0008963A (en)
CA (1) CA2363637A1 (en)
CO (1) CO5210906A1 (en)
CZ (1) CZ20013082A3 (en)
HK (1) HK1044004A1 (en)
HU (1) HUP0200049A2 (en)
IL (1) IL145024A0 (en)
MX (1) MXPA01008613A (en)
NO (1) NO20014130L (en)
NZ (1) NZ513679A (en)
PL (1) PL350993A1 (en)
TR (1) TR200102506T2 (en)
WO (1) WO2000050460A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
EP1497318A4 (en) * 2001-04-18 2006-03-01 Dyax Corp Binding molecules for fc-region polypeptides
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
WO2008099188A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
EP3882274A4 (en) * 2018-09-21 2022-06-29 Riken Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
JP2001516009A (en) * 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Cancer-related nucleic acids and polypeptides

Also Published As

Publication number Publication date
CN1348466A (en) 2002-05-08
KR20020007313A (en) 2002-01-26
PL350993A1 (en) 2003-02-24
TR200102506T2 (en) 2002-06-21
NO20014130D0 (en) 2001-08-24
NZ513679A (en) 2001-09-28
AU2672700A (en) 2000-09-14
MXPA01008613A (en) 2003-06-24
IL145024A0 (en) 2002-06-30
CO5210906A1 (en) 2002-10-30
JP2004538238A (en) 2004-12-24
BR0008963A (en) 2001-11-27
CA2363637A1 (en) 2000-08-31
EP1155037A1 (en) 2001-11-21
HK1044004A1 (en) 2002-10-04
HUP0200049A2 (en) 2002-05-29
AR029336A1 (en) 2003-06-25
CZ20013082A3 (en) 2002-02-13
WO2000050460A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
NO20014131D0 (en) Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications
NO20015362L (en) Heterocyclic substituted benzimidazoles, their preparation and use thereof
DE60015879D1 (en) spinal implant
ID25792A (en) ANTIBODIES OF HUMAN CD40
DE60003148D1 (en) Determination of the cache time
DE50014041D1 (en) USE OF EPINASTINE FOR THE TREATMENT OF ALLERGIC RHINITIS / CONJUNCTIVITIS
BR0014243B1 (en) Acoustic structure of construction.
NO20014130D0 (en) Epitopes or mimotopes derived from the C &lt;epsilon&gt; 2 domain of IgE, its antagonists and their therapeutic uses
NO20004144D0 (en) Heterocyclic compounds, their preparation and use as tachykinin receptor antagonists
NO20025423D0 (en) Procedure for the preparation of Citalopram
DE60028511D1 (en) Compensation of the probe chord error
DE60009587D1 (en) Determination of the paper level
DE50009938D1 (en) USE OF NANOSCALE GROWTH
NO992518D0 (en) element Organ
DE60026931D1 (en) Alignment of printouts
NO20023785D0 (en) Water-dispersible formulation of paroxetine
DE50006852D1 (en) USE OF NANOSCALE DEODORANTS
DE60011801D1 (en) BENZOXA AND BENZTHIAZOLYL SULFAMATE AND THEIR USE AS STEROID-SULFATASE INHIBITORS
DE60216307D1 (en) Stilbenamine derivatives and electrophotosensitive material using the same
ID30381A (en) USE OF ARILALKANOILPIRIDAZINA
DK1235809T3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as drugs
NO20005856L (en) Use of 1,1-dioxo-perhydro-1,2,4-thiadiazines
ZA200107015B (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
NO20015564L (en) Imidazo-containing heterocyclic compounds, their compositions and uses
ITUD20000026V0 (en) STRUCTURE OF THE BOTTOM OF AN AUTOCARAVAN OR SIMILAR

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application